|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600117215 |
|
最近更新日期: Date of Last Refreshed on: |
2026-01-21 10:17:03 |
|
注册时间: Date of Registration: |
2026-01-21 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于CCTA影像特征与深度学习技术的PCI术后MACE预测模型构建与评估 |
|
Public title: |
Construction and evaluation of prediction model of mace after PCI based on CCTA image characteristics and deep learning technology |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于CCTA影像特征与深度学习技术的PCI术后MACE预测模型构建与评估 |
|
Scientific title: |
Construction and evaluation of prediction model of mace after PCI based on CCTA image characteristics and deep learning technology |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
马开阳 |
研究负责人: |
马开阳 |
|
Applicant: |
Ma Kaiyang |
Study leader: |
Ma Kaiyang |
|
申请注册联系人电话: Applicant telephone: |
+86 15252580575 |
研究负责人电话: Study leader's telephone: |
+86 514 8653 2322 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
15252580575@163.com |
研究负责人电子邮件: Study leader's E-mail: |
362033934@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
扬州市江都区江洲路100号 |
研究负责人通讯地址: |
扬州市江都区江洲路100号 |
|
Applicant address: |
No. 100, Jiangzhou Road, Jiangdu District, Yangzhou |
Study leader's address: |
No. 100, Jiangzhou Road, Jiangdu District, Yangzhou |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
扬州大学附属江都人民医院 |
||
|
Applicant's institution: |
Jiangdu people's Hospital Affiliated to Yangzhou University |
||
|
研究负责人所在单位: |
扬州大学附属江都人民医院 |
||
|
Affiliation of the Leader: |
Jiangdu People’s Hospital Affiliated to Yangzhou University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
YJRY-2025-K-024 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
扬州大学附属江都人民医院伦理审查委员会 |
||
|
Name of the ethic committee: |
IRB of Jiangdu People’s Hospital Affiliated to Yangzhou University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-08-15 00:00:00 |
||
|
伦理委员会联系人: |
孙华雯 |
||
|
Contact Name of the ethic committee: |
Sun Huawen |
||
|
伦理委员会联系地址: |
扬州市江都区江洲路100号 |
||
|
Contact Address of the ethic committee: |
No. 100, Jiangzhou Road, Jiangdu District, Yangzhou |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 514 86536416 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
524037994@qq.com |
|
研究实施负责(组长)单位: |
扬州大学附属江都人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Jiangdu People’s Hospital Affiliated to Yangzhou University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
扬州市江都区江洲路100号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 100, Jiangzhou Road, Jiangdu District, Yangzhou |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
课题经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
Project funding |
||||||||||||||||||||||
|
Target disease: |
Coronary atherosclerotic heart disease |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
通过结合CCTA影像特征与深度学习技术,构建精准的预测模型,以评估PCI后MACE的发生风险。通过传统影像学特征与先进深度学习模型的比较与融合,旨在为临床提供一个更加科学、精准和个性化的风险评估工具,提升PCI后患者的预后预测能力,进而优化临床决策过程,降低不良事件发生率,最终改善患者的长期健康管理与生活质量。 |
||||||||||||||||||||||
|
Objectives of Study: |
By combining CCTA image features and deep learning technology, an accurate prediction model was constructed to evaluate the risk of mace after PCI. Through the comparison and integration of traditional imaging features and advanced deep learning model, it aims to provide a more scientific, accurate and personalized risk assessment tool for the clinic, improve the prognosis prediction ability of patients after PCI, optimize the clinical decision-making process, reduce the incidence of adverse events, and ultimately improve the long-term health management and quality of life of patients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄:18岁及以上,无上限年龄限制。2.疾病类型:必须在术前接受CCTA检查,并确认存在冠状动脉疾病(如稳定性心绞痛、急性冠脉综合症、急性心肌梗死等)。3.治疗标准:患者必须接受过PCI治疗,且手术完成后至少有12个月的随访数据。4.影像质量要求:CCTA影像质量需良好,且无严重伪影、运动伪影或图像模糊,能够提取有效的特征用于后续分析。5.数据完整性:患者的影像数据、临床信息以及随访数据完整,能够确保数据分析的准确性。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age: 18 years old and above, with no upper age limit. 2. Disease type: CCTA examination must be performed before surgery to confirm the presence of coronary artery disease (such as stable angina, acute coronary syndrome, acute myocardial infarction, etc.). 3. Treatment criteria: Patients must have undergone PCI treatment and have at least 12 months of follow-up data after the surgery is completed. 4. Image quality requirements: CCTA images must have good quality and be free of severe artifacts, motion artifacts, or image blurring, and be able to extract effective features for subsequent analysis. 5. Data integrity: The patient's imaging data, clinical information, and follow-up data are complete, ensuring the accuracy of data analysis. |
||||||||||||||||||||||
|
排除标准: |
1.影像质量差、随访数据缺失、严重合并症患者及无法进行术后随访的患者; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Poor image quality, missing follow-up data, patients with severe complications, and patients who cannot undergo postoperative follow-up. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-09-08 00:00:00至 To 2027-09-07 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-02-01 00:00:00 至 To 2027-09-07 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用多中心回顾性收集,标准化流程,DICOM格式存储,匿名化处理与质量控制。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Adopting multi center retrospective collection, standardized procedures, DICOM format storage, anonymization processing, and quality control. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |